Preserving Fertility in Breast Cancer Patients After Chemotherapy

Video
Conference|San Antonio Breast Cancer Symposium (SABCS)

This video highlights four abstracts from SABCS on preserving fertility in premenopausal breast cancer patients treated with chemotherapy.

In this video, Kathryn J. Ruddy, MD, MPH, of the Mayo Clinic in Rochester, Minnesota, discusses four abstracts on preserving fertility in premenopausal breast cancer patients treated with chemotherapy.

Ruddy was a discussant for a spotlight session on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS), held December 5–9 in San Antonio, Texas.

Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content
Bria-IMT Cancer Vaccine Shows Efficacy, Tolerability in Advanced Breast Cancer

Bria-IMT Cancer Vaccine Shows Efficacy, Tolerability in Advanced Breast Cancer

Tim Cortese
December 30th 2024
Article

A phase 1/2 study showed that treatment with cyclophosphamide, SV-BR-1-GM, and retifanlimab yields favorable survival data in heavily pretreated patients with breast cancer.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Andrew M. Evens, DO, MBA, MSc
December 9th 2024
Podcast

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Anito-cel produced no delayed or non–immune effector cell–associated neurotoxicity syndrome among patients with multiple myeloma.

Data Show Enduring Efficacy with Anito-cel in R/R Multiple Myeloma

Kristi Rosa
December 30th 2024
Article

Anito-cel produced no delayed or non–immune effector cell–associated neurotoxicity syndrome among patients with multiple myeloma.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Zanidatamab/Evorpacept Combo Yields Promising Activity in HER2+ Breast Cancer

Zanidatamab/Evorpacept Combo Yields Promising Activity in HER2+ Breast Cancer

Russ Conroy
December 28th 2024
Article

Phase 1b/2 data show antitumor activity with zanidatamab/evorpacept, including among heavily pretreated patients with HER2-low metastatic breast cancer.

Arlo-cel yields responses among patient subgroups, including those with triple class–refractory disease and extramedullary disease.

Arlo-cel Shows Promising Efficacy in Pretreated R/R Multiple Myeloma

Gina Mauro
December 27th 2024
Article

Arlo-cel yields responses among patient subgroups, including those with triple class–refractory disease and extramedullary disease.